Close Menu

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said on Monday that it has received clearance from the US Food and Drug Administration for the de novo submission of its Thermo Scientific QMS Plazomicin Immunoassay.

The quantitative immunoassay measures the concentration of a novel antibiotic, Zemdri (plazomicin), using the automated clinical chemistry analyzer Beckman Coulter AU 680.

Plazomicin is a next-generation aminoglycoside antibiotic that is used to treat patients with complicated urinary tract infections.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.